Patent Attorney's Docket No. <u>010830-117</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	In re I	Patent App	lication of)				
	Krzysztof MASTERNAK et al.)	Group Art	Unit: Unassigned		
	Application No.: Continuation of PCT/EP99/08026)		Unassigned	JCon	
	Filed:	April 24,	2001)				
	For:	MHC CI CAPABL TRANSC	CANSCRIPTION FACTOR LASS II GENES, SUBSTAI LE OF INHIBITING THIS I CRIPTION FACTOR AND LL USES OF THESE NCES	NCES)	1			
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER								
	Assistant Commissioner for Patents Washington, D.C. 20231							
	Sir:							
Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.								
	[X] No additional fee for submission of an IDS is required.							
	[] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed. [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.					1.17(p) is also enclosed.		
						losed.		
	[A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set fo in 37 C.F.R. § 1.17(p) are also enclosed. Charge \$					orth	
	[•	
		[] A check in the amount of \$ is enclosed for the fee due.						
į			issioner is hereby authorize 1.21 that may be required bo. 02-4800. This paper is s			oriate fees under 37 C.F.R. edit any overpayment, to		
				Respectfu	lly submitte	d,		
				Burns, D	OANE, SWE	CKER & MATHIS, L.L.P.		
A	.O. Box lexandri 703) 836	a, Virgini	a 22313-1404	By:Susa Reg	in M. Dadic istration No	40,373		

Date: April 24, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Krzysztof MASTERNAK et al.) Group Art Unit: Unassigned
Application No.: Continuation of PCT/EP99/08026) Examiner: Unassigned)
Filed: April 24, 2001)
For: NEW TRANSCRIPTION FACTOR OF MHC CLASS II GENES, SUBSTANCES CAPABLE OF INHIBITING THIS NEW TRANSCRIPTION FACTOR AND MEDICAL USES OF THESE SUBSTANCES)))

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. Also enclosed is the International Search Report.

U.S. PATENTS

1. Tang et al., U.S. Patent No. 5,989,863, issued November 23, 1999.

OTHER DOCUMENTS

 Milner et al., J. Biochem., 290:811-818 (1993) and abstract from Database PIR Online, Accession No. S30385 (XP-002117635).

- 3. Nagarajan et al., Immunity, 10:153-162 (1999).
- 4. Masternak et al., 31 Annual Meeting of the European Society of Human Genetics; Geneva, 7(Supplement):106 (1999).
- Abstract from Database EMBL Online, Accession No. AI051582,
 13 July 1998, R. Strausberg, "Soares fetal liver spleen INFLS S1;
 EST" (XP 002117632).
- Abstract from Database EMBL Online, Accession No. AD000812,
 March 1997, J.E. Lamerdin, "Homo sapiens DNA from chromosome 19-cosmid R27740 containing MEF2B and RSRFR2 genes, genomic sequence" (XP 002117633).
- Abstract from Database EMBL Online, Accession No. AC003110,
 January 1998, J.E. Lamerdin, "F14150 1 (FRAGMENT).
 Related to AC003110" (XP 002117634).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Xusai

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: April 24, 2001